TMO · US market
Thermo Fisher Scientific Inc
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$241.26bnFinancials dated 27 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- US$6.97bn
- Latest-quarter run-rate earnings
- US$6.94bn
- Latest fiscal-year earnings
- US$6.70bn
- Trailing revenue
- US$46.34bn
- Latest-quarter run-rate revenue
- US$47.98bn
- Latest fiscal-year revenue
- US$44.56bn
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- FSMEX · Fidelity Select Medical Technology and Devices Portfolio14.06% weight · Holdings dated 31 May 2026
- EAALX · Eaton Vance-Atlanta Capital Focused Growth Fund Class A8.65% weight · Holdings dated 30 June 2026
- WVAIX · Weitz Large Cap Equity Fund - Institutional Class5.85% weight · Holdings dated 30 June 2026
- CSIEX · Calvert Equity Fund Class A4.73% weight · Holdings dated 30 June 2026
- GDOC · Goldman Sachs Future Health Care Equity ETF4.52% weight · Holdings dated 31 May 2026
- ESEAX · Eaton Vance Atlanta Capital Select Equity Fund Class A4.45% weight · Holdings dated 30 June 2026
- TMED · T. Rowe Price Health Care ETF4.11% weight · Holdings dated 30 June 2026
- BMED · iShares Health Innovation Active ETF4.11% weight · Holdings dated 21 August 2026
- XLV · State Street Health Care Select Sector SPDR ETF3.60% weight · Holdings dated 19 August 2026
- IYH · iShares U.S. Healthcare ETF3.46% weight · Holdings dated 19 August 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 27 June 2026. Informational research, not investment advice.